Loading
Life sciences · Journal article
Macromol—a Journal of Macromolecular Research · September 5, 2026
Early or partial results. Treat as a signal, not a conclusion.
This preclinical study reports that water-soluble moringa seed lectin (WSMoL) reduced visceral adiposity, dyslipidemia, hyperglycemia, and pro-inflammatory cytokines in diet-induced obese mice. However, the highest dose (4 mg/kg) was associated with elevated liver enzymes and persistent inflammatory tissue changes, raising safety concerns and limiting translational value at present.
Preclinical in vivo study; mouse model with multiple treatment arms and sham control. Male Swiss mice; induction group fed high-fat diet plus condensed milk; sham group on standard chow. Intervention: Water-soluble lectin from Moringa oleifera seeds (WSMoL) at doses of 1, 2, or 4 mg/kg, intraperitoneal injection. Compared with: Phosphate-buffered saline (negative control) and orlistat 40 mg/kg.
WSMoL improved metabolic parameters at all doses (1, 2, 4 mg/kg), reducing visceral fat and attenuating hyperglycemia WSMoL decreased pro-inflammatory cytokines IL-2, IFN-γ, TNF-α, and IL-6 while increasing IL-10 levels WSMoL prevented hepatic steatosis and renal lipid accumulation
Safety signal (elevated AST at 4 mg/kg dose) limits highest-dose efficacy claims; mechanism of organ stress not explored.
This result is restricted to animal models and does not yet warrant clinical application. The emergence of organ stress markers (elevated AST) and incomplete tissue recovery at higher doses suggest that dose-finding and safety pharmacology work must precede any consideration of human trials.
Single-centre, uncontrolled animal study with surrogate endpoints and safety concerns at the highest dose; results do not yet support clinical translation.
As stated by the source record.
Quoted from the source exactly as published.
This result is restricted to animal models and does not yet warrant clinical application. The emergence of organ stress markers (elevated AST) and incomplete tissue recovery at higher doses suggest that dose-finding and safety pharmacology work must precede any consideration of human trials.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Moringa oleifera Lam. seeds contain lectins that exhibit interesting bioactive properties, but their effects on metabolic syndrome (MetS) remain poorly understood. This work evaluated the effects of the water-soluble lectin from M. oleifera seeds (WSMoL) on metabolic, inflammatory, and histopathological alterations in a mouse model of MetS-like features. Male Swiss mice were fed a high-fat diet plus condensed milk solution for 11 weeks. Animals then received phosphate-buffered saline (negative control), orlistat (40 mg/kg), or WSMoL (1, 2, or 4 mg/kg, i.p.) for 14 days. A healthy group (Sham) received standard chow. The MetS-like protocol induced obesity, hyperglycemia, dyslipidemia, visceral adiposity, and systemic inflammation. WSMoL improved metabolic parameters at all doses, reducing visceral fat, attenuating hyperglycemia, and improving the lipid profile. It also decreased pro-inflammatory cytokines (IL-2, IFN-γ, TNF-α, and IL-6) while increasing IL-10 levels. WSMoL prevented hepatic steatosis and renal lipid accumulation, although inflammatory and degenerative tissue changes persisted. The 4 mg/kg dose showed efficacy but was associated with elevated AST and more frequent inflammatory alterations. In conclusion, WSMoL mitigated key features of MetS-like condition, although incomplete tissue recovery and signs of organ stress at the highest dose warrant caution regarding its potential therapeutic use.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.